9,620 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Carlyle Group Inc.

Carlyle Group Inc. acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYREFree Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,620 shares of the company’s stock, valued at approximately $227,000. Spyre Therapeutics comprises 0.0% of Carlyle Group Inc.’s investment portfolio, making the stock its 27th largest position.

A number of other institutional investors have also recently made changes to their positions in SYRE. Quest Partners LLC purchased a new position in shares of Spyre Therapeutics in the second quarter valued at $36,000. SG Americas Securities LLC bought a new position in Spyre Therapeutics in the 2nd quarter worth about $130,000. TD Asset Management Inc purchased a new position in Spyre Therapeutics during the 2nd quarter valued at about $827,000. EFG Asset Management North America Corp. bought a new stake in shares of Spyre Therapeutics during the second quarter valued at about $869,000. Finally, Rhumbline Advisers purchased a new stake in shares of Spyre Therapeutics in the second quarter worth about $1,220,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Price Performance

Shares of Spyre Therapeutics stock opened at $29.36 on Monday. Spyre Therapeutics, Inc. has a 1 year low of $8.43 and a 1 year high of $47.97. The firm has a market cap of $1.18 billion, a PE ratio of -0.41 and a beta of 2.92. The company has a 50 day simple moving average of $27.84 and a two-hundred day simple moving average of $32.05.

Spyre Therapeutics (NASDAQ:SYREGet Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. As a group, research analysts anticipate that Spyre Therapeutics, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SYRE. Wedbush assumed coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They set an “outperform” rating and a $45.00 price objective for the company. Evercore ISI initiated coverage on shares of Spyre Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating for the company. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $43.43.

View Our Latest Stock Analysis on Spyre Therapeutics

Spyre Therapeutics Company Profile

(Free Report)

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Further Reading

Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYREFree Report).

Institutional Ownership by Quarter for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.